z-logo
open-access-imgOpen Access
False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care
Author(s) -
Stephany Tandy-Connor,
Jenna Guiltinan,
Kate Krempely,
Holly LaDuca,
Patrick Reineke,
Stephanie Gutierrez,
Phillip Gray,
Brigette Tippin Davis
Publication year - 2018
Publication title -
genetics in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.509
H-Index - 128
eISSN - 1530-0366
pISSN - 1098-3600
DOI - 10.1038/gim.2018.38
Subject(s) - concordance , false positive paradox , genetic testing , medicine , raw data , population , genotyping , personal genomics , food and drug administration , medical genetics , genomics , genetics , gene , genotype , computer science , biology , medical emergency , genome , environmental health , machine learning , programming language
There is increasing demand from the public for direct-to-consumer (DTC) genetic tests, and the US Food and Drug Administration limits the type of health-related claims DTC tests can market. Some DTC companies provide raw genotyping data to customers if requested, and these raw data may include variants occurring in genes recommended by the American College of Medical Genetics and Genomics to be reported as incidental/secondary findings. The purpose of this study was to review the outcome of requests for clinical confirmation of DTC results that were received by our laboratory and to analyze variant classification concordance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom